Important Note: Retatrutide is currently an investigational drug and not yet FDA-approved for general clinical use
Variants like GLP1R rs6923761 and FTO rs9939609 can suggest how your body may respond to GLP-1 agonism, informing whether you might benefit from optimized monotherapyoften enough to avoid the risks of dual-agent approaches
The four primary mechanisms are: signaling the hypothalamus to suppress hunger, slowing gastric emptying so fullness lasts longer, stimulating insulin release after meals to prevent blood sugar spikes, and suppressing glucagon to reduce glucose release from the liver
Focus on non-scale victories like reduced hunger and improved meal control during the first two weeks
The body starts adapting to the new caloric intake and metabolic state during this phase
Before choosing to start a new medication, discuss your health goals, insurance coverage, and any potential side effects with your healthcare provider to find the most effective and safe treatment.